Skip Ribbon Commands
Skip to main content
Navigate Up
Search
Test Code
Search
Laboratory Section
Test Category
Browse By Test Name
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Ganglioside Antibody Panel, Serum (GM1B)
Test Code: GANGPSO
Synonyms/Keywords
​Anti-GM1 Antibody, Asialo GM-1 Antibody, Disialo GD1b, GM1 Antibody Panel, Monosialo GM-1 Antibody
Test Components
Reflex titers will be performed as needed.
 
IgG Monosialo GM1 Titer
IgM monosialo GM1 Titer
IgG asialo GM1 Titer
IgM asialo GM1 Titer
IgG disialo GD1b Titer
IgM disialo GD1b Titer
Useful For
Supporting diagnosis of neurological diseases-primarily motor neuron disease and motor neuropathies​
Specimen Requirements
 
Specimen Type Preferred Container/Tube Acceptable Container/Tube Specimen Volume Specimen Minimum Volume
(allows for 1 repeat)
Pediatric Minimum Volume
(no repeat)
Serum​ ​Red Top Tube (RTT) ​Serum Separator Tube (SST) ​1.0 mL 0.5 mL
Collection Processing Instructions
Spin down primary collection tube and submit serum in a plastic vial.
Specimen Stability Information
Specimen Type Temperature Time
​Serum ​ ​ ​Refrigerated (preferred) ​28 days
​Room Temperature 72 hours
​Frozen ​28 days
Rejection Criteria
Gross Hemolysis
Gross Lipemia
Performing Laboratory Information
 
Performing Location Day(s) Test Performed Analytical Time Methodology/Instrumentation
​Mayo Clinic Laboratories Monday, Wednesday​ ​6 days
Quantitative Enzyme-Linked Immunosorbent Assay (ELISA)​
Reference Lab
Test Information

Screening tests are performed for IgG and IgM antibodies to GM1 and GD1b. If positive, the appropriate titer will be performed at an additional charge.

Useful for supporting diagnosis of neurological diseases, primarily motor neuron disease and motor neuropathies. Ganglioside antibodies are polyclonal autoantibodies produced at high levels directed against ganglioside (GM1 and GD1b) antisera. Gangliosides are sphingolipids that are important components of neural cell membranes. Typically, multifocal motor neuropathy begins with asymmetric upper limb weakness which becomes more generalized over many years. Sensory function is spared and reflexes are normal. The weak limbs may have atrophic muscles with fasciculation. On a clinical basis, these patients may be mistakenly diagnosed as suffering from amyotrophic lateral sclerosis (ALS). Patients with multifocal motor neuropathy do not have prominent upper motor neuron signs (spasticity) and bulbar weakness is extremely unusual. The multifocal motor neuropathy may be associated with characteristic electrophysiologic changes of conduction block in motor nerve pathways. In the clinical evaluation of patients with lower motor neuron disease or motor neuropathy, measurement of antiganglioside antibodies has become part of the diagnostic evaluation. In patients with a confirmed diagnosis of multifocal motor neuropathy, biopsy of affected nerve has shown an intensive inflammatory infiltrate in the area of conduction block. The implication of the antiganglioside antibodies and the inflammatory infiltrates in nerve is that this disorder represents an immune-mediated neuropathy which may respond to immunosuppression. Reports from other institutions and experience at Mayo Clinic have confirmed that some patients with multifocal motor neuropathy do respond well to immunosuppression. It is, therefore, important to distinguish clearly between patients with motor neuron disease and those with motor neuropathy. The estimation of antiganglioside antibodies provides 1 component of the evaluation.

Reference Range Information
Profile Information:
IGG_M: Negative
IGM_M: Negative
IGG_A: Negative
IGM_A: Negative
IGG_D: Negative
IGM_D: Negative
 
Reflex Information:
IGMTS: <1:2000
IMMTS: <1:4000
IGATS: <1:16000
IMATS: <1:8000
IGDTS: <1:2000
IMDTS: <1:2000
Interpretation

High titers (>1:2,000) have been found only in patients with multifocal motor neuropathy and not with motor neuron disease. About 30% to 50% of patients with these clinical syndromes or the pure motor variant of chronic inflammatory demyelinating polyneuropathy have increased antibody titers. Increased antibody titers, therefore, appear to be a specific but not sensitive marker of those related disorders.

  For IgG and IgM antibodies directed against monosialo GM1 and disialo GD1b, 99% of 182 age- and sex-stratified normal individuals had titers <1:1,000; 99% of 121 patients with well-defined motor neuron disease had titers <1:2,000; and all patients with titers >1:2,000 had motor neuropathy.

Outreach CPTs
 
CPT Modifier
(if needed)
Quantity Description Comments
​83516​ ​6 Ganglioside Antibody Panel, Serum (GM1B)
​83520 ​1-​6 ​Reflexed testing ​As needed
Synonyms/Keywords
​Anti-GM1 Antibody, Asialo GM-1 Antibody, Disialo GD1b, GM1 Antibody Panel, Monosialo GM-1 Antibody
Test Components
Reflex titers will be performed as needed.
 
IgG Monosialo GM1 Titer
IgM monosialo GM1 Titer
IgG asialo GM1 Titer
IgM asialo GM1 Titer
IgG disialo GD1b Titer
IgM disialo GD1b Titer
Ordering Applications
Ordering Application Description
​Centricity ​Ganglioside Antibody Panel (83189)
​Cerner ​Ganglioside Antibody Panel (83189)
If the ordering application you are looking for is not listed, contact your local laboratory for assistance.
Specimen Requirements
 
Specimen Type Preferred Container/Tube Acceptable Container/Tube Specimen Volume Specimen Minimum Volume
(allows for 1 repeat)
Pediatric Minimum Volume
(no repeat)
Serum​ ​Red Top Tube (RTT) ​Serum Separator Tube (SST) ​1.0 mL 0.5 mL
Collection Processing Instructions
Spin down primary collection tube and submit serum in a plastic vial.
Specimen Stability Information
Specimen Type Temperature Time
​Serum ​ ​ ​Refrigerated (preferred) ​28 days
​Room Temperature 72 hours
​Frozen ​28 days
Rejection Criteria
Gross Hemolysis
Gross Lipemia
Useful For
Supporting diagnosis of neurological diseases-primarily motor neuron disease and motor neuropathies​
Test Information

Screening tests are performed for IgG and IgM antibodies to GM1 and GD1b. If positive, the appropriate titer will be performed at an additional charge.

Useful for supporting diagnosis of neurological diseases, primarily motor neuron disease and motor neuropathies. Ganglioside antibodies are polyclonal autoantibodies produced at high levels directed against ganglioside (GM1 and GD1b) antisera. Gangliosides are sphingolipids that are important components of neural cell membranes. Typically, multifocal motor neuropathy begins with asymmetric upper limb weakness which becomes more generalized over many years. Sensory function is spared and reflexes are normal. The weak limbs may have atrophic muscles with fasciculation. On a clinical basis, these patients may be mistakenly diagnosed as suffering from amyotrophic lateral sclerosis (ALS). Patients with multifocal motor neuropathy do not have prominent upper motor neuron signs (spasticity) and bulbar weakness is extremely unusual. The multifocal motor neuropathy may be associated with characteristic electrophysiologic changes of conduction block in motor nerve pathways. In the clinical evaluation of patients with lower motor neuron disease or motor neuropathy, measurement of antiganglioside antibodies has become part of the diagnostic evaluation. In patients with a confirmed diagnosis of multifocal motor neuropathy, biopsy of affected nerve has shown an intensive inflammatory infiltrate in the area of conduction block. The implication of the antiganglioside antibodies and the inflammatory infiltrates in nerve is that this disorder represents an immune-mediated neuropathy which may respond to immunosuppression. Reports from other institutions and experience at Mayo Clinic have confirmed that some patients with multifocal motor neuropathy do respond well to immunosuppression. It is, therefore, important to distinguish clearly between patients with motor neuron disease and those with motor neuropathy. The estimation of antiganglioside antibodies provides 1 component of the evaluation.

Reference Range Information
Profile Information:
IGG_M: Negative
IGM_M: Negative
IGG_A: Negative
IGM_A: Negative
IGG_D: Negative
IGM_D: Negative
 
Reflex Information:
IGMTS: <1:2000
IMMTS: <1:4000
IGATS: <1:16000
IMATS: <1:8000
IGDTS: <1:2000
IMDTS: <1:2000
Interpretation

High titers (>1:2,000) have been found only in patients with multifocal motor neuropathy and not with motor neuron disease. About 30% to 50% of patients with these clinical syndromes or the pure motor variant of chronic inflammatory demyelinating polyneuropathy have increased antibody titers. Increased antibody titers, therefore, appear to be a specific but not sensitive marker of those related disorders.

  For IgG and IgM antibodies directed against monosialo GM1 and disialo GD1b, 99% of 182 age- and sex-stratified normal individuals had titers <1:1,000; 99% of 121 patients with well-defined motor neuron disease had titers <1:2,000; and all patients with titers >1:2,000 had motor neuropathy.

For more information visit:
Performing Laboratory Information
 
Performing Location Day(s) Test Performed Analytical Time Methodology/Instrumentation
​Mayo Clinic Laboratories Monday, Wednesday​ ​6 days
Quantitative Enzyme-Linked Immunosorbent Assay (ELISA)​
Reference Lab
For billing questions, see Contacts
Outreach CPTs
 
CPT Modifier
(if needed)
Quantity Description Comments
​83516​ ​6 Ganglioside Antibody Panel, Serum (GM1B)
​83520 ​1-​6 ​Reflexed testing ​As needed
For most current information refer to the Marshfield Laboratory online reference manual.